Protective Action of Anandamide and Its COX-2 Metabolite against L-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes

Guangbi Li, Min Xia, Justine M. Abais, Krishna Boini, Pin-Lan Li, and Joseph K. Ritter

Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia

Received March 1, 2016; accepted April 28, 2016

ABSTRACT
Recent studies have demonstrated that L-homocysteine (Hcys)-induced podocyte injury leading to glomerular damage or sclerosis is attributable to the activation of the nucleotide-binding oligomerization domain–like receptor containing pyrin domain 3 (NLRP3) inflammasome. Given the demonstrated anti-inflammatory effects of endocannabinoids, the present study was designed to test whether anandamide (AEA) or its metabolite can diminish NLRP3 inflammasome activation and prevent podocyte injury and associated glomerular damage during hyperhomocysteinemia (hHcys). AEA (100 μM) inhibited Hcys-induced NLRP3 inflammasome activation in cultured podocytes, as indicated by elevated caspase-1 activity and interleukin-1β levels, and attenuated podocyte dysfunction, as shown by reduced vascular endothelial growth factor production. These effects of AEA were inhibited by the cyclooxygenase-2 (COX-2) inhibitor celecoxib (CEL). In mice in vivo, AEA treatment attenuated glomerular NLRP3 inflammasome activation induced by hHcys accompanying a folate-free diet, on the basis of inhibition of hHcys-induced colocalization of NLRP3 molecules and increased interleukin-1β levels in glomeruli. Correspondingly, AEA prevented hHcys-induced proteinuria, albuminuria, and glomerular damage observed microscopically. Hcys- and AEA-induced effects were absent in NLRP3-knockout mice. These beneficial effects of AEA against hHcys-induced NLRP3 inflammasome activation and glomerular injury were not observed in mice cotreated with CEL. We further demonstrated that prostaglandin E2-ethanolamide (PGE2-EA), a COX-2 product of AEA, at 10 μM had a similar inhibitory effect to that of 100 μM AEA on Hcys-induced NLRP3 inflammasome formation and activation in cultured podocytes. From these results, we conclude that AEA has anti-inflammatory properties, protecting podocytes from Hcys-induced injury by inhibition of NLRP3 inflammasome activation through its COX-2 metabolite, PGE2-EA.

Introduction
It has been well established that elevated serum homocysteine level, namely, hyperhomocysteinemia (hHcys), is associated with a wide range of diseases and pathologic processes, including neurologic (Ravaglia et al., 2005; Bialecka et al., 2012; Perla-Kaján and Jakubowski, 2012), cardiovascular (Cavalca et al., 2001; Bialecka et al., 2012) and kidney (Wu et al., 2012) disease, osteoporosis (McLean et al., 2004), and complications of aging (Yu et al., 2012). With respect to glomerulosclerosis and consequent end-stage renal disease (ESRD), a large body of evidence supports a pathogenic role of Hcys via its effects on extracellular matrix accumulation, mesangial expansion, podocyte injury, local oxidative stress, and inflammation (Yi et al., 2007; Zhang et al., 2010; Li et al., 2013). Further mechanistic studies have recently demonstrated that the activation of nucleotide-binding oligomerization domain–like receptor containing pyrin domain 3 (NLRP3) inflammasomes is a triggering mechanism leading to podocyte injury and glomerular sclerosis during hHcys (Zhang et al., 2012; Han et al., 2013; Abais et al., 2014a; Xia et al., 2014). This type of inflammasome consists of NLRP3 protein, the adaptor molecule apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and the cysteine protease caspase-1, forming a cytosolic multiprotein complex that catalyzes the production of interleukin (IL)-1β, IL-18, and other products like high-mobility group protein B1 (Martinon and Tschopp, 2005; Sutterwala et al., 2007). It is imperative that this NLRP3 inflammasome be studied as a potential therapeutic target for prevention and treatment of glomerulosclerosis and ESRD during hHcys.

In previous studies, although endocannabinoids have been reported to have the proinflammatory role in the development of inflammation under certain pathologic conditions (Vercelli

This study was supported by National Institutes of Health National Institute of Diabetes and Digestive and Kidney Disease [Grants DK102539 and DK54927] and National Heart, Lung, and Blood Institute [Grants HL75316 and HL57244].

Contributed equally to this work.

dx.doi.org/10.1124/jpet.116.233239.

ABBREVIATIONS: AEA, anandamide; ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; CEL, celecoxib; COX-2, cyclooxygenase-2; ESRD, end-stage renal disease; FF, folate-free; GDI, glomerular damage index; Hcys, L-homocysteine; hHcys, hyperhomocysteinemia; IL, interleukin; KO, knockout; LPS, lipopolysaccharide; ND, normal diet; NLRP3 (gene), NALP3 (protein), nucleotide-binding oligomerization domain–like receptor containing pyrin domain 3; PGE2-EA, prostaglandin E2-ethanolamide; VEGF, vascular endothelial growth factor; WT, wild-type.
et al., 2009; Gatta et al., 2012), numerous reports have shown that endocannabinoids exert anti-inflammatory action in a variety of experimental models of inflammatory disease, including experimental hepatitis (Hegde et al., 2008), inflammatory bowel disease (Di Sabatino et al., 2011), lipopolysaccharide (LPS)-induced pulmonary inflammation (Berdyshiev et al., 1998), nephropathy (Mukhopadhyay et al., 2010a; Mukhopadhyay et al., 2010b), and multiple sclerosis (Mestre et al., 2005). Among endocannabinoids, anandamide (AEA) has been documented to exert anti-inflammatory effects, but it has also been considered as a source of proinflammatory factors (Gatta et al., 2012). AEA can be metabolized by eicosanoid biosynthetic enzymes and therefore its role against inflammation may be associated with effects of its own and its metabolites on different inflammatory pathways (Turcotte et al., 2015). For example, cyclooxygenase-2 (COX-2) inhibition has been reported to block IL-2 release induced by AEA in mouse splenocytes and to prevent transcriptional activity of the IL-12p40 gene induced by AEA (Correa et al., 2008). Prostaglandin E2-ethanolamide (PGE2-EA), a COX-2-derived metabolite of AEA, attenuated cytokine-evoked epithelial damage in human mucosal explant colitis and reduced LPS-induced tumor necrosis factor-α production in monocytes (Brown et al., 2013). It is clear that AEA and its COX-2 metabolite, PGE2-EA, have potent anti-inflammatory effects. However, the molecular mechanism remains elusive.

In the present study, we hypothesized that AEA and its metabolite may inhibit NLRP3 inflammasome activation in podocytes and thereby prevent glomerular inflammation and sclerosis during hHcys. To test this hypothesis, we first addressed whether AEA inhibits podocyte NLRP3 inflammasome formation and activation and prevents glomerular injury and sclerosis induced by hHcys in vivo in wild-type (WT) or NLRP3 gene knockout (KO) (Nlrp3<sup>−/−</sup>) mice. NLRP3 knockout mice show resistance to hHcys-associated development of podocyte injury and glomerulosclerosis (Xia et al., 2014). We also determined whether COX-2 inhibition ameliorates the beneficial effects of AEA. Then, we went on to examine whether PGE2-EA is the active metabolite of AEA that inhibits NLRP3 inflammasome activation and protects podocytes against 1-homocysteine (Hcys)-induced dysfunction and injury.

**Materials and Methods**

**Cell Culture.** Conditionally immortalized mouse podocytes, kindly provided by Dr. Paul Klotman (Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY), were cultured and maintained as described previously (Abais et al., 2013, 2014b). Briefly, they were grown at the permissive temperature (33°C) on collagen I-coated flasks or plates in RPMI 1640 medium supplemented with 10% fetal bovine serum and 10 IU/ml recombinant mouse interferon-γ. The podocytes were then passaged and allowed to differentiate at 37°C for 10–14 days without interferon-γ before use in the experiments described below. Podocytes were treated with Hcys (40 μM, prepared in water) for 24 hours, a dose and treatment time optimized in earlier studies.

**Animals.** Eight-week-old male C57BL/6J WT and NLRP3 KO mice were used in the present study. To speed up the damaging effects of hHcys on glomeruli, all mice were uninephrectomized as described previously (Boini et al., 2011, 2012). This model has been demonstrated to induce glomerular damage unrelated to the uninephrectomy and arterial blood pressure but specific to hHcys. After a 1-week recovery period from uninephrectomy, mice were fed either normal diet (ND) or folate-free (FF) diet (Dyets, Inc., Bethlehem, PA) for 4 weeks. At the same time, different groups of mice received AEA at 10 mg/kg per day with or without CEL at 2 mg/kg per day i.p. injection, on the basis of previous studies (DeMorrow et al., 2008; Zheng et al., 2008). All protocols involving animals were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University.

**Immunofluorescence Microscopy.** Double-immunofluorescence staining was performed using cultured podocytes grown on collagen-coated glass cover slips and frozen mouse kidney sections as described previously (Zhang et al., 2012; Abais et al., 2013, 2014b). Briefly, after fixation, the cells were incubated with goat anti-NLRP3 (Abcam, Cambridge, MA), followed by incubation with Alexa 488-labeled donkey anti-goat secondary antibody (1:200; Life Technologies/Thermo Fisher Scientific, Sunnyvale, CA). Then, rabbit anti-ASC or rabbit anti-caspase-1 (1:100; Santa Cruz Biotechnology, Dallas, TX) was added to the cell slides and then incubated overnight at 4°C. To examine the distribution of F-actin fibers in podocytes, F-actin was stained with rhodamine-phalloidin (Invitrogen/Thermo Fisher Scientific) for 15 minutes at room temperature as described previously (Abais et al., 2013). Frozen mouse kidney sections were fixed in acetone, blocked, then incubated with the same aforementioned primary antibodies overnight at 4°C. Some cover slips with podocytes and frozen kidney sections were only stained for podocyte markers podocin (1:100; Sigma-Aldrich, St. Louis, MO) or desmin (1:100; BD Biosciences, San Jose, CA). Double immunofluorescent staining was performed by Alexa Fluor 488- or Alexa Fluor 555-labeled secondary antibody (1:200; Invitrogen) incubation for 1 hour at room temperature. Slides were then washed, mounted, and observed using a confocal laser scanning microscope (FluoView FV1000, Olympus, Tokyo, Japan). Image Pro Plus software (v. 6.0; Media Cybernetics, Bethesda, MD) was used to analyze colocalization, which was expressed as the Pearson correlation coefficient.

**Caspase-1 Activity, IL-1β, and Vascular Endothelial Growth Factor Measurements.** Caspase-1 activity was measured by a commercially available colorimetric assay (BioVision Inc., Milpitas, CA), and IL-1β production and vascular endothelial growth factor (VEGF)-α secretion were measured in the supernatant of cultured podocytes using an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions.

**Immunohistochemistry.** Fixed kidney tissues were embedded in paraffin and 5-μm sections were cut. After heat-induced antigen retrieval, slides were washed with 3% hydrogen peroxide, blocked with control serum for 30 minutes, and then incubated with primary antibody diluted in phosphate-buffered saline containing 4% blocking serum. Anti-IL-1β (Abcam) antibody was used in this study. After incubation with primary antibody overnight, the sections were washed in phosphate-buffered saline and incubated with biotinylated IgG (1:200) for 1 hour and then with streptavidin-conjugated horse-radish peroxidase for 30 minutes at room temperature. The peroxidase substrate, 3,3′-diaminobenzidine (50 μl), was added to each section and stained for 1 minute. After washing, the slides were counterstained with hematoxylin for 5 minutes prior to mounting and imaging by light microscopy.

**Urinary Protein and Albumin Measurements.** Total urinary protein excretion was determined spectrophotometrically using the Bradford assay (Sigma-Aldrich), and urinary albumin excretion was measured using a commercially available mouse albumin enzyme-linked immunosorbent assay kit (Bethyl Laboratories, Montgomery, TX).

**Gomorphologic Examinations.** Fixed kidney tissues were paraffin-embedded, sectioned, and stained with periodic acid–Schiff. Glomerular morphology was observed and assessed semiquantitatively by light microscopy as described previously (Raju et al., 1984; Abais et al., 2014b).
Results

Protective Action of AEA at Different Concentrations against Hcys-Induced NLRP3 Inflammasome Activation and Injury via Its COX-2 Metabolites in Cultured Podocytes. We first tested the effects of AEA at increasing concentrations up to 100 μM. As shown in Fig. 1, A and B, AEA was found to have significant inhibitory effects on Hcys-induced elevations in caspase-1 activity and IL-1β production in a concentration-dependent manner. Only at 100 μM was the inhibitory effect of AEA on NLRP3 inflammasome activation significant. When the podocytes were cotreated with the selective COX-2 inhibitor CEL, the effects of AEA observed at high concentrations were completely blocked. As an indicator of Hcys-induced podocyte injury (Boini et al., 2012; Zhang et al., 2012), the secretion of VEGF and AEA was markedly reduced, almost completely, by Hcys at a concentration of 100 μM. In the presence of CEL, AEA failed to reverse Hcys-induced secretion of VEGF (Fig. 1C).

COX-2-Dependent Protection of Glomerular Podocytes by AEA against Hcys-Induced NLRP3 Inflammasome Formation and Activation in Mice In Vivo. We next examined whether AEA has protective effects against the formation and activation of NLRP3 inflammasomes in podocytes of mice with hHcys. After 4 weeks on an FF diet, all uninephrectomized mice developed hHcys, with an average concentration of plasma Hcys level at 25 ± 3 μM, compared with 6 ± 2 μM in mice on the ND, even in NLRP3 gene KO mice (Nlrp3−/−) (data not shown). As shown in Fig. 2, A and B, confocal microscopic analysis showed the formation of NLRP3 inflammasomes in glomeruli of wild-type (WT) mice with hHcys, as shown by increased colocalization of NLRP3 with ASC or caspase-1, but not in Nlrp3−/− mice. However, AEA given at 10 mg/kg per day i.p. over the time period of FF diet exposure substantially suppressed the increased colocalization of NLRP3 with ASC or caspase-1 in glomeruli of WT mice with Hcys. This AEA-mediated inhibitory effect on the assembly of NLRP3 inflammasomes during hHcys was completely blocked by CEL. The Pearson correlation coefficient data for colocalization of NLRP3 with ASC or caspase-1 is summarized in the bar graphs on the bottom of representative images. It is clear that the colocalization of NLRP3 with ASC or caspase-1 significantly increased in glomeruli of WT mice, but not in Nlrp3−/− on the FF diet. This increase in the formation of NLRP3 inflammasomes in glomeruli was not observed when they were treated with AEA, but it remained in mice treated with both AEA and CEL.

Correspondingly, the IL-1β level as an indicator of NLRP3 inflammasome activation was remarkably elevated in WT mice on the FF diet but was not altered in mice on the ND, as shown in immunohistochemical stained photomicrographs (Fig. 2C). In the mice receiving AEA treatment or with NLRP3 gene deletion, however, the FF diet failed to increase the IL-1β level in glomerular podocytes. When these mice were administered CEL, the effects of AEA treatment on the IL-1β increase during hHcys disappeared. CEL had no effect on the IL-1β level in the glomeruli of Nlrp3−/− mice no matter whether these mice received AEA or not. As shown in the bar graph of Fig. 2C, the increase in IL-1β level during hHcys was significantly attenuated only in the group of mice receiving AEA alone.

Prevention by AEA of hHcys-Induced Glomerular Damage in Mice In Vivo. To determine whether AEA inhibition of NLRP3 inflammasome activation prevents glomerular injury in mice during hHcys, we analyzed changes in urinary protein and albumin excretion and morphologic integrity of glomeruli. Figure 3, A and B, shows that WT mice on the FF diet had significant increases in urinary protein and
albumin excretion compared with WT mice on the ND. In Nlrp3−/− mice, even with the FF diet, there were no changes in urinary protein and albumin excretion. In WT mice receiving AEA, urinary protein and albumin excretion had no changes during hHcys, whereas those mice cotreated with AEA and CEL showed remarkable proteinuria and albuminuria. Morphologically, FF diet-fed WT but not Nlrp3−/− mice displayed glomerular pathology, characterized by increased extracellular matrix, including collagen deposition, capillary collapse, and mesangial cell expansion (Fig. 3C). AEA treatment prevented these glomerular destructive changes induced by hHcys. In WT mice cotreated with AEA and CEL, however, the glomerular sclerotic changes remained profound. As shown in the bar graphs of Fig. 3C, the glomerular damage index (GDI) of FF diet-fed WT mice but not Nlrp3−/− mice was significantly increased. AEA treatment completely blocked the FF diet-induced increase in the GDI of WT mice, but AEA and CEL cotreatment had no effect on the increase in GDI by FF diet.

Amelioration by AEA of hHcys-Induced Podocyte Injury in Mice. To further determine whether the protective effects of AEA against hHcys-induced glomerular damage associated with NLRP3 inflammasome activation are attributable to its actions on podocytes, we measured the expression levels of podocin and desmin, because reduction of podocin and increase in desmin indicate podocyte injury. Immunofluorescent microscopy demonstrated that FF diet-fed WT mice displayed marked decrease in podocin level and dramatic increase in desmin level, but ND-fed WT mice and all groups of Nlrp3−/− mice did not. In the FF diet-fed WT mice receiving AEA, however, there were no changes in the expression of both podocin and desmin. AEA blocked the FF diet-induced increase in the GDI of WT mice, whereas AEA and CEL cotreatment had no effect on the increase in GDI by FF diet.

Inhibition of Hcys-Induced NLRP3 Inflammasome Formation by PGE2-EA in Cultured Podocytes. Given that the major product of AEA metabolism via COX-2 is PGE2-EA, we next tested whether PGE2-EA is protective against Hcys-induced formation and activation of NLRP3 inflammasome and injury in podocytes. By confocal microscopy, we examined whether PGE2-EA has effects on Hcys-induced NLRP3 inflammasome formation. As shown in Fig. 5, exposure of podocytes to Hcys (40 μM) significantly increased colocalization of NLRP3 with ASC (Fig. 5A) or caspase-1 (Fig. 5B). In the presence of PGE2-EA (10 μM), Hcys-enhanced colocalization of NLRP3 with ASC or caspase-1 in podocytes was substantially attenuated. However, cotreatment of podocytes with the same concentration of AEA (10 μM), the precursor to PGE2-EA, had no effect on Hcys-induced NLRP3 inflammasome formation. The Pearson correlation coefficient data for colocalization of NLRP3 with ASC or caspase-1 are shown in the bar graphs to the right of each representative image. Statistically, PGE2-EA was found to significantly inhibit Hcys-induced colocalization of NLRP3 with ASC or caspase-1, whereas AEA at the same concentration did not alter this Hcys-induced colocalization of the inflammasome components.

Blockade by PGE2-EA of Hcys-Induced NLRP3 Inflammasome Activation in Cultured Podocytes. We also examined whether outcomes of Hcys-induced NLRP3

![Fig. 2. COX-2-dependent protection of glomerular podocytes by AEA against hHcys-induced NLRP3 inflammasome formation and activation in mice. (A) Images showing the colocalization between NLRP3 (green) with ASC (red) in glomeruli of mice receiving either normal diet or folate-free diet and the different treatments shown with summarized data (n = 6). (B) Images showing the colocalization between NLRP3 (green) with caspase-1 (red) in glomeruli from different groups and summarized data (n = 6). (C) Images showing IL-1β immunoreactivity in glomeruli from different groups of mice and summarized data (n = 6). *p < 0.05 versus WT-Vehicle (Vehl)-ND group, #p < 0.05 versus WT-Vehl-FF group.](https://jpet.aspetjournals.org/article-figures/64/Li-Fig2.png)
inflammasome activation in cultured podocytes can likewise be affected by PGE2-EA or AEA. Treatment with Hcys significantly increased caspase-1 activity as measured by microplate fluorospectrometric analysis. Cotreatment of these podocytes with PGE2-EA (10 μM) almost abolished Hcys-induced increase in podocyte caspase-1 activity, but AEA cotreatment did not have such effect (Fig. 6A). Similarly, the elevation in IL-1β level in culture medium of podocytes treated with Hcys was blocked by PGE2-EA but not by AEA at the same concentration (Fig. 6B).

Protective Effect of PGE2-EA Against Hcys-Induced Injury to Cultured Podocytes. To determine whether PGE2-EA prevents podocyte morphologic changes and dysfunction associated with Hcys-induced NLRP3 inflammasome formation and activation, F-actin fiber arrangement and VEGF production in podocytes as structural and functional parameters were examined under different treatments. Immunofluorescent microscopy showed that Hcys resulted in loss of the distinct arrangement of F-actin fibers observed in control cells, as shown by their condensation at cell edges in fluorescent staining. This Hcys-induced rearrangement of F-actin fibers in podocytes was largely prevented by PGE2-EA cotreatment but not by AEA. The intensity quantitation of F-actin fluorescent staining showed that Hcys-induced loss of F-actin in podocytes was significantly suppressed by PGE2-EA but not by AEA at the same concentration (Fig. 7A). It was also found that Hcys markedly reduced VEGF secretion in podocytes, and this reduction of VEGF secretion was substantially blocked by cotreatment with PGE2-EA but not with AEA (Fig. 7B).

We also examined the effects of PGE2-EA on the expression of podocin and desmin to further evaluate its protective action on podocytes upon Hcys stimulation. Under basal condition, the cultured podocytes were found to highly express podocin. After treatment with Hcys, the podocin staining was significantly reduced, but such reduction was blocked by cotreatment of these cells with PGE2-EA. AEA cotreatment at the same concentration, however, had little apparent ability to
block this Hcys-induced decrease in podocin. The intensity analysis showed that in podocytes cotreated with PGE2-EA, Hcys induced significantly less reduction of podocin expression (Fig. 8A) compared with control and AEA cotreated cells. In contrast, desmin was found to be overexpressed in response to Hcys treatment. This Hcys-induced overexpression of desmin in podocytes was significantly decreased by PGE2-EA but was not affected by AEA (Fig. 8B).

Discussion

The present study was designed to determine whether AEA or its COX-2 metabolite, PGE2-EA, can prevent hHcys-induced podocyte injury and glomerular damage through inhibition of NLRP3 inflammasome formation and activation. We demonstrated that AEA can suppress the activation of NLRP3 inflammasome and prevent podocyte injury and dysfunction associated with hHcys. However, the beneficial effects of AEA were blocked or attenuated by cotreatment with the selective COX-2 inhibitor CEL. These results suggest that PGE2-EA is the active metabolite of AEA that inhibits NLRP3 inflammasome formation and activation and protects podocytes against Hcys-induced dysfunction and injury, preventing glomerular damage or sclerosis during hHcys.

Although endocannabinoids, including AEA and its metabolites, in some cases may produce proinflammatory actions, a large body of evidence supports potent anti-inflammatory actions in a variety of inflammatory diseases. For example, AEA has been reported to inhibit inflammatory responses in experimental hepatitis (Hegde et al., 2008), inflammatory bowel disease (Di Sabatino et al., 2011), LPS-induced pulmonary inflammation (Berdyshev et al., 1998), nephropathy (Mukhopadhyay et al., 2010a, b), and multiple sclerosis (Mestre et al., 2005). Additional studies demonstrate that elevation of AEA levels by genetic knockout or chemical inhibition of the AEA degradative enzyme fatty acid amide...
and IL-1 endocannabinoid attenuated Hcys-enhanced caspase-1 activity masome activation in podocytes. It was found that this dependent inhibition by AEA of Hcys-induced NLRP3 inflam-massome formation in glomeruli, as shown by reduced aggregation of inflammasome components by confocal microscopy. Consistent with inhibitory effects on inflammasome formation, AEA also strongly inhibited increased IL-1β production resulting from the FF diet. Functional studies showed that hHcys-induced elevations of urinary protein and albumin were remarkably attenuated by AEA. Correspondingly, it was found that AEA prevented podocyte injury and mesenchymal cell expansion following hHcys-induced NLRP3 inflammasome activation by immunofluorescent staining and immunohistochemistry, respectively. To our knowledge, these results represent the first experimental evidence that AEA can significantly attenuate podocyte damage associated with Hcys-induced NLRP3 inflammasome activation in vivo. Since podocyte injury is a critical step in the initiation and development of glomerular sclerosis or ESRD (Asanuma and Mundel, 2003), this protective effect of AEA on Hcys-induced NLRP3 inflammasome activation could represent a useful strategy for preventing the progression of glomerular injury during hHcys.

Several laboratories have reported inhibitory effects on inflammation and associated diseases and pathologic phe-nomena by elevating endogenous AEA levels through different approaches, including fatty acid amide hydrolase gene KO (Naidu et al., 2010; Kinsey et al., 2011; Wang et al., 2015), fatty acid amide hydrolase inhibitors (Kinsey et al., 2011; Schuelert et al., 2011; Booker et al., 2012; Caprioli et al., 2012; Kerr et al., 2012; Murphy et al., 2012; Sasso et al., 2012; Krustev et al., 2014; Salaga et al., 2014; Tchantchou et al., 2014), and AEA reuptake inhibitors (Mestre et al., 2005; Argenio et al., 2006). Further studies are needed to address whether such approaches are also protective in glomerular injury associated with hHcys. Our finding that exogenous AEA produces anti-inflammatory effects is consistent with several reports documenting beneficial effects of exogenous AEA in inflammatory disease models, such as liver damage (Hegde et al., 2008), LPS-induced pulmonary inflammation...
(Berdyshev et al., 1998), periodontitis (Rettori et al., 2012), hypoxia-ischemia injury (Lara-Celador et al., 2012), delayed-type hypersensitivity (Jackson et al., 2014), and viral de-myelinating disease (Hernangomez et al., 2012).

Since a recent report showed that COX-2 products of AEA exert protective effects against inflammation (Turcotte et al., 2015), we also investigated the role of COX-2 in the mechanism of AEA’s protective effects against NLRP3 inflammasome activation and podocyte and glomerular injury from hHcys. The presence of the COX-2 inhibitor CEL attenuated the protective effects of AEA on markers of Hcys-induced NALP3 (nucleotide-binding oligomerization domain–like receptor containing pyrin domain 3) inflammasome activation and injury to cultured podocytes (Fig. 1), and it was also found to block or attenuate the protective in vivo effects of exogenous AEA on various indicators of hHcys-associated NALP3 inflammasome activation and sequelae (Figs. 2–4). Although these findings support the capacity of podocytes to metabolize AEA to PGE2-EA, the current study did not address this question directly. However, AEA is known to be present in the renal cortex, including in glomerular elements (Deutsch et al., 1997; Ritter et al., 2012), and podocytes express cyclooxygenases, including COX-2 (Lemieux et al., 2003).

Next, we performed in vitro experiments to determine if the COX-2 product of AEA was active as an inhibitor of NLRP3 inflammasome activation. It has been well established that COX-2 metabolism of AEA leads to a diverse array of prostaglandin ethanolamides, including PGG2-EA, PGH2-EA, PGD2-EA, PGE2-EA, PGF2α-EA, and PGI2-EA (Yu et al., 1997; Kozak et al., 2002; Koda et al., 2004; Yang et al., 2005). In this regard, PGE2-EA, one of the most studied COX-2 metabolites of AEA, has been reported to inhibit inflammation in different disease models. Inhibition of IL-12p40 production by AEA acting on the promoter repressor element GA-12 was mimicked by PGE2-EA and was partially reversed by the selective COX-2 inhibitor NS-398 (Correa et al., 2008). PGE2-EA has been demonstrated to reduce epithelial damage evoked by proinflammatory cytokines, tumor necrosis factor-α, and IL-1β in an ex vivo human mucosal explant colitis model (Nicotra et al., 2013). Correspondingly, PGE2-EA was found to down-regulate the production of tumor necrosis factor-α by human mononuclear cells in response to an immune stimulus, LPS-activated Toll-like receptor 4 (Brown et al., 2013). On the basis of this information, we hypothesized that PGE2-EA may be the active COX-2 metabolite of AEA inhibiting NLRP3 inflammasome activation. Our results showed that PGE2-EA (10 μM) significantly inhibited the formation and activation of NLRP3 inflammasome and prevented podocyte injury in the presence of Hcys. In contrast, it was found that AEA (10 μM)
had no significant effect on Hcys-induced NLRP3 inflammasome activation and podocyte injury. These results suggest that PGE2-EA is responsible at least in part for the inhibitory effects of AEA on NLRP3 inflammasome activation, preventing podocyte injury and glomerular damage during hHcys.

In summary, the present study demonstrates a novel anti-inflammatory role of AEA and, in particular, the COX-2 metabolite of AEA, PGE2-EA, on hHcys-induced NLRP3 inflammasome activation. This action of PGE2-EA is associated with inhibition of podocyte injury and glomerular damage during hHcys. These results may establish a new therapeutic strategy for hHcys-induced glomerular sclerosis by inhibition of NLRP3 inflammasome activation.

**Authorship Contributions**

**Participated in research design:** Li, Xia, Boini, Li, Ritter.
**Conducted experiments:** G, Li, Xia, Ritter.
**Performed data analysis:** Li, Xia, Li, Ritter.
**Wrote or contributed to the writing of the manuscript:** Li, Xia, Li, Ritter.

**References**


E328.


Downloaded from jpet.aspetjournals.org at ASPECT Journals on May 22, 2021